Mental health reforms ‘mark vital step' in improving care quality
Patients would be given a greater say over their care and treatment under the terms of the Mental Health Bill tabled in Parliament.
Other changes include ensuring that detention and compulsory treatment are only undertaken when necessary, with provision for more frequent reviews and appeals, and limiting the time people with autism or a learning disability can be detained.
The Bill has already been scrutinised in the House of Lords and is being debated in the House of Commons on Monday evening.
Mr Streeting told MPs: 'The measure of a society is how it treats its most vulnerable citizens. When it comes to the treatment of people with serious mental illness, we are falling well short of the humane, compassionate society we aspire to be.
'Patients live 15 to 20 years shorter lives than the average. They are often accommodated far away from their family and loved ones.
'The facilities they are housed in can be completely unsuitable. Lord Darzi found during his investigation last year nearly 20 patients in a mental health facility forced to share two showers and live amongst an infestation of rats and cockroaches.
'Patients are denied the basic choice and agency that is awarded to NHS patients with physical illnesses. People from ethnic minority communities, and especially black African and Caribbean men, are more than three times as likely to be sectioned.
'Although they are very different conditions, people with a learning disability or autistic people are often lumped in with those who have mental illness – reflecting an outdated lack of medical understanding.'
Mr Streeting added: 'While attitudes to mental health have come on leaps and bounds in the past four decades, the law has been frozen in time.
'As a result, the current legislation fails to give patients adequate dignity, voice and agency in their care.
'This is despite the fact that patients themselves have consistently told us that being treated humanely and making decisions about their own care plays a vital role in their recovery.
'When patients are detained and treated without any say over what is happening to them, it can have serious consequences for their ongoing health.'
Mr Streeting went on: 'This Bill does not solve every problem in our mental health services, but it marks a vital step in our plans to improve the quality of care, combat long-standing inequalities and bring about a stronger focus on prevention and early intervention in mental health.'
Mr Streeting said mental health professionals will 'have to consider the risk of serious harm when making decisions to detain' which will ensure 'any risks to the public and patients are considered as part of the assessment process'.
He said: 'The vast majority of people with mental illness, including severe mental illness, present no risk to themselves or others and for the majority of people, treatment can be provided without compulsion.
'However, there are some people whose illness, when acutely unwell, can make them a risk to themselves and sometimes to others.
'No one knows this better than the families of Ian Coates, Barnaby Webber or Grace O'Malley Kumar, the victims of Valdo Calocane's violent rampage in Nottingham, whose campaign for justice and accountability has been truly awe inspiring, or indeed the family of Valdo Calocane, who I have also spent time with listening to their experience of feeling badly let down by health services.
'As the independent investigation into the murders found, both he and his victims were failed by the health service, and the families are left to live through the consequences in a level of pain the rest of us could scarcely imagine.'
Shadow health secretary Ed Argar welcomed the Bill, saying it's 'not only important but right that our laws are updated to reflect the modern world and the knowledge we have today'.
He said: 'I believe it is right that we took the time to get this right. That work updating the Mental Health Act started under the previous government, and we had a commitment in our election manifesto to update the laws in this area, and that is something that has been carried on by the new government, and we continue to believe this is the right thing to do.
'So I want to put on record our in principle, support for the Government in this legislation.'
He told MPs the Conservative 'welcome efforts to improve the patient's voice involvement in their own care' through 'greater use of advanced choice documents'.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sky News
39 minutes ago
- Sky News
GPs can prescribe weight loss jabs on the NHS from today - but strict eligibility criteria in place
Why you can trust Sky News GPs will be able to prescribe weight loss jabs on the NHS from today. - with strict criteria for the first year of the rollout. Initially, only those with a body mass index of over 40 who have at least four other health problems linked to obesity will be eligible. 0:21 Some doctors have raised concerns about the additional workload this new programme will bring, while pharmacists fear it could lead to supply shortages. While an estimated 1.5 million people are now taking weight loss drugs across the UK, they could previously only be accessed through specialist services or private prescriptions. Dr Claire Fuller from NHS England said: "We urgently need to address rising levels of obesity and prioritise support for those who are experiencing severe ill health - and greater access to weight loss drugs will make a significant difference to the lives of those people." She added: "While not everyone will be eligible for weight loss drugs, it's important that anyone who is worried about the impact of their weight on their health discusses the range of NHS support available with their healthcare professional." 1:22 The chairwoman of the Royal College of GPs welcomed NHS England's decision to pursue a phased rollout, and said current workloads must be factored in to ensure the jabs can be prescribed safely. Professor Kamila Hawthorne went on to say: "While weight loss medications have a lot of potential benefits for patients who are struggling to lose weight and who meet all the clinical criteria for a prescription, they mustn't be seen as a 'silver bullet' to aid weight loss. "We also need to see a focus on prevention, stopping people becoming overweight in the first place so they don't require a medical intervention later." 9:19 Her remarks were echoed by the National Pharmacy Association's chairman Olivier Picard, who says "prescribing these medications alone misses the point". He argued that they need to be part of a comprehensive strategy that includes lifestyle coaching, exercise and nutritional guidance - but many GPs currently "lack the bandwidth" to provide this support. "As a result, we could end up in a situation where patients are prescribed the medication, lose weight, and then experience rebound weight gain once the course ends - simply because the foundational lifestyle changes weren't addressed," Mr Picard added. Estimates suggest about 29% of the adult population is obese.
Leader Live
3 hours ago
- Leader Live
Mass rollout of weight loss jabs begins on NHS
Around 220,000 people with 'greatest need' are expected to receive Mounjaro, also known as tirzepatide and made by Lilly through the NHS over the next three years. The drug is an antidiabetic drug which lowers blood sugar levels and and slows down how quickly food is digested. From Monday, GPs in England will be allowed to prescribe Mounjaro to severely obese people who also suffer from a range of other health problems. Patients previously needed to access the drugs through a special weight loss service. But leading family doctors said some GPs have expressed concern about the additional workload linked to the rollout. And pharmacy experts also said there could be pressure on supplies of the drug. In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of over 40 who have at least four other health problems linked to obesity, such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea. Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription. Dr Claire Fuller, from NHS England, said: 'This is an important next step in the rollout of weight loss drugs, with community-based services now able to offer this treatment from today. 'We urgently need to address rising levels of obesity and prioritise support for those who are experiencing severe ill health – and greater access to weight loss drugs will make a significant difference to the lives of those people. 'These drugs are an important tool alongside the range of wraparound NHS support and advice on good nutrition and increasing physical activity, which will be vital in helping some people lose weight and reduce their risk of serious long-term conditions. 'While not everyone will be eligible for weight loss drugs, it's important that anyone who is worried about the impact of their weight on their health discusses the range of NHS support available with their healthcare professional.' Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'While we recognise the potential benefits of weight loss drugs, we know many GPs are concerned about the implications of the rollout of weight loss drugs into general practice, both in terms of workload and training to appropriately initiate and manage these treatments. 'The college shares these concerns, which is why we were pleased NHS England suggested a phased roll-out of Mounjaro as a treatment for weight loss. As and when this is escalated, appropriate resourcing for general practice – including access to 'wraparound' services – and training for GPs must follow. GLP-1s like #Ozempic, #Saxenda, #Wegovy, or #Mounjaro are not an easy #weightloss hack. Find out more about:🔵what they are ❓🔵how they're used 💊🔵who they help 💪 🔗Learn more: — EU Medicines Agency (@EMA_News) January 4, 2025 She added: 'GPs and our teams are already working under intense workload and workforce pressures, and this must be factored into this rollout in order to guarantee it can be delivered safely. 'More widely, whilst weight loss medications have a lot of potential benefits for patients who are struggling to lose weight and who meet all the clinical criteria for a prescription, they mustn't be seen as a 'silver bullet' to aid weight loss. 'We also need to see a focus on prevention, stopping people becoming overweight in the first place so they don't require a medical intervention later.' Dr Hawthorne said there is no 'one size fits all approach' and that the rollout of the jabs should not 'come at the expense of other weight loss service'. She continued: 'The roll-out of weight loss medications in the NHS will need to be consistently evaluated to ensure that there is evidence that these prescriptions are of long-term benefit to patients.' Olivier Picard, chairman of the National Pharmacy Association, said: 'The demand for weight loss jabs continues to rise sharply, and more GPs have been directing patients back to pharmacies after initial inquiries, to access these treatments privately. 'As the NHS is now moving to implement National Institute for Health and Care Excellence (Nice) guidance, and tirzepatide becomes prescribable to more patients, we expect to see prescription volumes increase rapidly. 'However, NHS provision won't meet demand straight away, so we fully expect that many people will continue seeking it privately from a pharmacy. 'Pharmacists are experts in medication and many of us have lots of experience delivering weight loss injections as part of a package of care including lifestyle advice. 'We are well placed to help roll out weight loss treatment on the NHS, with the right funding to support it. 'The biggest concern we have is that prescribing these medications alone misses the point. 'They should be part of a comprehensive weight management strategy – combining lifestyle coaching, exercise, and nutritional guidance. In reality, many GPs lack the bandwidth to deliver the level of support needed to ensure proper understanding and follow-up. 'As a result, we could end up in a situation where patients are prescribed the medication, lose weight, and then experience rebound weight gain once the course ends – simply because the foundational lifestyle changes weren't addressed.' Around 29% of the adult population in the UK is obese. Health Secretary Wes Streeting said: 'Obesity is now one of the leading causes of ill health, costing the NHS billions. Yet we now have the science, technology, and knowledge to end the obesity epidemic, if we seize this opportunity. 'Obesity jabs are used by 1.5 million people in the UK, mainly through private prescriptions. The NHS was founded on a promise to 'universalise the best', and this Government is determined to bring revolutionary modern treatments to everyone who needs them, not just those who can afford to pay. 'This rollout is an important step in making these medicines more widely available, and beginning to shift the focus of healthcare from sickness to prevention, which our forthcoming 10-year plan will deliver.'
Leader Live
3 hours ago
- Leader Live
Mounjaro weight loss jab: All you need to know
Some 220,000 people with the 'greatest need' are expected to receive Mounjaro, also known as tirzepatide and made by Lilly, through the NHS over the next three years. Here the PA news agency takes a look at the drug and the rollout. – How does tirzepatide work? Tirzepatide, or Mounjaro, is an antidiabetic drug which lowers blood sugar levels and slows down how quickly food is digested. It makes you feel fuller for longer and therefore less hungry. If the jab is recommended by a healthcare professional, those using it will need to eat a balanced, reduced-calorie diet and to exercise regularly while taking it, according to the NHS website. – Who might be eligible for the drug? In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of more than 40 who have at least four other health problems linked to obesity, such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea. It was previously only accessible to patients through a special weight loss service, to severely obese people who also suffer from a range of other health problems. Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription. – How would it be administered? The drug is usually delivered through a self-administered weekly injection which a doctor or nurse will show patients how to use, the NHS website says. – Who cannot take tirzepatide? Mounjaro is not recommended for those who are pregnant or planning to get pregnant, breastfeeding or have certain health conditions, according to the NHS. For those taking the contraceptive pill and using tirzepatide, the NHS recommends using an additional method of contraception, such as a condom, for the first four weeks of treatment and for four weeks after each dose increase as the contraceptive pill may not be absorbed by the body during this time. – What are the potential side effects? Potential side effects of tirzepatide include nausea, vomiting, diarrhoea and constipation, according to the National Institute for Health and Care Excellence.
